CYDY - CytoDyn: Buy Sell Or Hold Following PRO 140 Commercial Agreement

CytoDyn Inc. (OTCQB:CYDY) recently publicized that they have signed a U.S. commercial agreement with Vyera for PRO 140 in HIV indications. In return, CytoDyn will receive an upfront payment and milestone payments worth up to the royalty on net sales. This was one of the most anticipated catalysts remaining in 2019 and the stock responded appropriately by doubling in value in a couple of days. Typically, I would shave a portion of my position and hold the rest following good news, but I decided to sit on my hands in this case. PRO